Despite their good performance in limiting tumor growth in preclinical and clinical studies, dose limiting toxicities such as diarrhea, skin rash, and an increase of transaminase have been found to be associated with pharmacological inhibitors of mTOR signaling (44). This evidence concerns the gene MTOR and neoplasm.